Stockreport

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity a [Read more]